Nurix Therapeutics Inc.
NRIX | NASDAQ
$25.41
-$0.03 (-0.12%)
At close: Sep 21, 2026, 4:00 PM ET
$25.40
-$0.01 (-0.04%)
Pre-market:
Sep 22, 2026, 5:28 AM ET
Fiscal Year Period Ending | FY 2025 Nov 29, 2025 | FY 2024 Nov 29, 2024 | FY 2023 Nov 29, 2023 | FY 2022 Nov 29, 2022 | FY 2021 Nov 29, 2021 | FY 2020 Nov 29, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -5.54 | -7.68 | -2.35 | -3.34 | -10.56 | -15.44 |
PEG Ratio | -0.94 | -0.88 | 0.08 | -0.09 | 9.71 | -0.04 |
PS Ratio | 17.45 | 27.21 | 4.39 | 15.59 | 41.55 | 37.49 |
PB Ratio | 2.72 | 2.82 | 1.69 | 1.98 | 3.61 | 2.30 |
P/FCF Ratio | -5.56 | -8.16 | -3.77 | -3.50 | -13.73 | -144.18 |
P/OCF Ratio | -5.87 | -8.60 | -4.15 | -3.77 | -14.65 | -8.35K |
OCF/S Ratio | -297.05 | -316.38 | -105.69 | -413.72 | -283.58 | -0.45 |
Debt / Equity Ratio | 0.10 | 0.05 | 0.15 | 0.04 | 0.04 | n/a |
Quick Ratio | 7.02 | 6.46 | 3.40 | 4.52 | 4.70 | 6.70 |
Current Ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 | 6.70 |
Asset Turnover | 0.12 | 0.08 | 0.22 | 0.09 | 0.06 | 0.04 |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -49.09% | -36.73% | -71.80% | -59.39% | -34.24% | -14.90% |
Return on Assets | -38.43% | -28.92% | -40.48% | -43.28% | -24.58% | -10.91% |
Return on Invested Capital | -47.26% | -36.63% | -56.16% | -52.29% | -28.45% | -12.52% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 77.55% | -306.30% | -145.69% | -377.64% | -291.37% | -273.14% |
Net Profit Margin | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% | -242.66% |
Pretax Profit Margin | -314% | -354.36% | -186.98% | -466.93% | -393.49% | -357.90% |
Operating Profit Margin | -340.16% | -390.52% | -201.41% | -476.01% | -396.26% | -364.66% |
FCF Margin | -313.73% | -333.38% | -116.60% | -445.42% | -302.61% | -26% |
EBITDA Margin | -291.55% | -339.66% | -179.01% | -456.19% | -386.80% | -352.43% |
Add to Watchlist
Select watchlists to add or remove NRIX